Simpson Thacher Represents JPMorgan in Connection With Financing for Repligen’s Acquisition of C Technologies
04.29.19
This is only gets display when printing
The Firm is representing JPMorgan Chase Bank, N.A., in connection with the bank financing related to Repligen Corporation’s announced agreement to acquire C Technologies for approximately $240 million. To fund the transaction, Repligen intends to use its cash on hand, which totaled approximately $194 million at December 31, 2018 and potentially a committed bank debt financing of $125 million obtained by JPMorgan. JPMorgan is serving as lender, lead arranger and the sole administrative agent under the committed financing. The transaction is expected to be completed during the second quarter of 2019, subject to the satisfaction of customary closing conditions.
Repligen Corporation (NASDAQ:RGEN) is a global bioprocessing company that develops and commercializes highly innovative products that deliver cost and process efficiencies to biological drug manufacturers worldwide. C Technologies, Inc. is a privately-held, Bridgewater, NJ based company known for innovation in spectroscopy. The company designs and manufactures assemblies, instrumentation and systems for spectroscopy applications, primarily for biotech and pharmaceutical customers, and also for government, research institutions and academia.
The Simpson Thacher team includes Jessica Tuchinsky (Banking and Credit); David Azarkh and Mary-Jane Rabeony (Capital Markets); Michael Isby (Environmental); Alysha Sekhon (IP); Erik Ward (ECEB); and Jessica Levy (Tax).